$48.5 B

Novartis Revenue FY, 2016
Novartis Revenue growth (FY, 2015 - FY, 2016), %(2%)
Novartis Gross profit (FY, 2016)31 B
Novartis Gross profit margin (FY, 2016), %63.9%
Novartis Net income (FY, 2016)6.7 B

Novartis Revenue

Novartis revenue was $48.52 b in FY, 2016 which is a 1.8% year over year decrease from the previous period.

Embed Graph

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 67.1% from Innovative Medicines, 20.9% from Sandoz and 12.0% from Alcon

Novartis Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

Revenue

53.6 b49.4 b48.5 b

Revenue growth, %

(8%)(2%)

Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b

Gross profit Margin, %

68%65%64%

Sales and marketing expense

12.4 b11.8 b12 b

R&D expense

9.1 b8.9 b9 b

General and administrative expense

2.6 b2.5 b2.2 b

Operating expense total

25.2 b24 b23.6 b

Interest expense

704 m655 m707 m

Interest income

31 m454 m447 m

Net Income

10.3 b17.8 b6.7 b

Novartis Cash Flow

Annual

USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b

Novartis Ratios

USDY, 2016

Revenue/Employee

407.7 k
Report incorrect company information

Novartis Operating Metrics

Y, 2015Y, 2016

Major Approvals (US, EU, JP)

20 16

Major Submissions (US, EU, JP)

14 24

Patients Reached

972 m965 m

Phase III Trials Products

37 29

Projects Entering Development Pipeline

8 5

US FDA Breakthrough Therapy Designations

5
Report incorrect company information